Takeda Announces New Assignments of Directors
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
OSAKA, Japan, July 12, 2023 – Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/about/corporate-governance/charters-and-reports/
This report is prepared based on the current Corporate Governance Code. It describes the latest corporate governance features of our Company, including the new structure of the Board of Directors after the 147th General Shareholder’s Meeting held on June 28, 2023.
Key elements of Takeda’s Corporate Governance Report:
Takeda ensures transparency and objectivity of the Board of Directors’ discussion by further increasing the composition ratio of Independent External Directors (three Internal Directors and 12 Independent External Directors) and having an independent external director serve as the Chair of the Board meeting.
The Board of Directors is composed of diverse members with various background, experiences and knowledge (BOD Skill Matrix), to help enable strategic discussions and effective supervision of the Company.
The Audit and Supervisory Committee, and the Nomination/Compensation Committees as advisory committees for the Board of Directors are composed entirely of Independent External Directors, including each head/chairperson, in order to ensure the independence of each committee.
Takeda’s management receive a certain level of delegation of authority from the Board of Directors, and the Takeda Executive Team, which is diverse in terms of background, nationality, gender, and age, ensures agile and efficient decision-making based on strategic discussions at the management committee meetings.
Takeda’s latest Corporate Governance Report can be found on the information disclosure site operated by the Japan Exchange Group which consists of the TSE and other exchanges in Japan at: https://www2.jpx.co.jp/tseHpFront/CGK020010Action.do?Show=Show
Takeda also furnished the English version of the Corporate Governance Report with the U.S. Securities and Exchange Commission (the “SEC”), available at http://www.sec.gov .
Additionally, Takeda’s corporate governance strategy as well as overall sustainability and Environmental, Social and Governance information are explained in detail in its 2023 Annual Integrated Report for the fiscal year ended March 31, 2022, which was issued on July 6. This report can be accessed on Takeda’s website at: https://www.takeda.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/annual-integrated-report/
*TSE’s Securities Listing Regulations [Rule 419].
Takeda is focused on creating better health for people and a brighter future for the world. We aimto discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries andregions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Jun Saito [email protected]
U.S. and International Media
Megan Ostrower [email protected] +1 772-559-4924